Utility of cynomolgus monkey, Macaca fascicularis, in Pharmacological Studies
Cynomolgus macaques are anatomically and physiologically close to humans. Their similarity in brain anatomy, including cerebrovasculature, make cynomolgus macaques an ideal species for preclinical neuroscience studies. In addition, because of high similarity between humans and macaques in a number of proteins, macaques are uniquely suited as an animal species for drug safety as well as efficacy screening.
Macaques are generally not used for pharmacology/efficacy screening of drug candidates for a number of reasons:
Availability: Limited number of cynomolgus macaque-based disease models;
Expertise: Limited number of scientists and support staff experienced/skilled in NHP handling;
Cost: Macaques are resource-intensive.
HPR scientists and staff are experienced in a number of NHP disease models and endpoint evaluation in an AAALAC International-accredited study environment.
HPR provides high quality pharmacological services to support drug development in various therapeutic areas.
Importance of the NHP Models
Potential discrimination in the preclinical phase between therapeutics that may be effective or ineffective
Pharmacologically validated NHP models
Biochemical parameters associated with thrombosis are similar to those in humans
In NHP pain models, quantified pain-related behaviors
Please contact us for more details concerning our NHP models and services